These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16807442)

  • 1. A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
    Zustovich F; Cartei G; Dal Bianco M; De Zorzi L; Ceravolo R; Zovato S; Salmaso F; Binato S; Artioli G; Cingarlini S; Pastorelli D
    Ann Oncol; 2006 May; 17 Suppl 5():v133-6. PubMed ID: 16807442
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
    Neri B; Doni L; Gemelli MT; Fulignati C; Turrini M; Di Cello V; Dominici A; Maleci M; Mottola A; Ponchietti R; Raugei A; Valsuani G; Cini G
    J Urol; 2002 Sep; 168(3):956-8. PubMed ID: 12187198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapeutic treatment for metastatic renal carcinoma].
    Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
    Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma].
    Inoue T; Ohyama C; Hatakeyama S; Horikawa Y; Togashi H; Tsuchiya N; Matsuura S; Satoh S; Sato K; Habuchi T
    Hinyokika Kiyo; 2005 Mar; 51(3):165-9. PubMed ID: 15852669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
    Donini M; Buti S; Lazzarelli S; Bozzetti R; Rivoltini L; Camisaschi C; Castelli C; Bearz A; Simonelli C; Lo Re G; Mattioli R; Caminiti C; Passalacqua R;
    Target Oncol; 2015 Jun; 10(2):277-86. PubMed ID: 25230695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
    Buti S; Lazzarelli S; Chiesa MD; Simonelli C; Re GL; Lheshi A; Simon S; Mattioli R; Caminiti C; Mazza G; Donini M; Passalacqua R;
    J Immunother; 2010 Sep; 33(7):735-41. PubMed ID: 20664353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
    Buti S; Brighenti M; Bongiovanni C; Buzio C; Chiesa MD; Alberici F; Passalacqua R
    J Immunother; 2007 Oct; 30(7):780-6. PubMed ID: 17893570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperplasia of axillary nodes in patients undergoing immunotherapy.
    Loyer E; David C; Sella A; Ellerhorst J
    AJR Am J Roentgenol; 1997 Nov; 169(5):1359-62. PubMed ID: 9353459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of gemcitabine at fixed infusion rate of 10 mg/m2/min with or without immunotherapy in advanced renal cancer.
    Zustovich F; Cartei G; Pastorelli D; Nicoletto O; Gottardo F; De Zorzi L; Dal Bianco M
    Anticancer Res; 2007; 27(6C):4461-4. PubMed ID: 18214061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of renal cancer patients with gemcitabine (2',2'-difluorodeoxycytidine) and interferons: antitumor activity and toxicity.
    Rohde D; Thiemann D; Wildberger J; Wolff J; Jakse G
    Oncol Rep; 1998; 5(6):1555-60. PubMed ID: 9769405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Multi-enzyme-targeted" immunochemotherapy: a salvage therapy protocol.
    Klein HO; Demir G
    Anticancer Res; 1999; 19(4C):3451-8. PubMed ID: 10629634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
    van Herpen CM; De Mulder PH
    Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
    Doehn C; Jocham D
    Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).
    Pandha H
    Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
    Ryan CW; Vogelzang NJ; Stadler WM
    Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
    Porta C; Zimatore M; Imarisio I; Natalizi A; Sartore-Bianchi A; Danova M; Riccardi A
    Cancer; 2004 May; 100(10):2132-8. PubMed ID: 15139055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
    Stadler WM; Vogelzang NJ
    Semin Oncol; 1995 Feb; 22(1):67-73. PubMed ID: 7855621
    [No Abstract]   [Full Text] [Related]  

  • 18. Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy.
    Paolorossi F; Villa S; Barni S; Tancini G; Andres M; Lissoni P
    Tumori; 1995; 81(1):45-7. PubMed ID: 7754541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 20. Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer.
    Tucci M; Stucci S; Vallarelli S; Gesualdo L; Brunetti O; Dei Tos AP; Silvestris F
    J Clin Oncol; 2015 May; 33(14):e66-70. PubMed ID: 24663052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.